Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFMW) Operating Income (2016 - 2025)

Historic Operating Income for Sunshine Biopharma (SBFMW) over the last 13 years, with Q3 2025 value amounting to -$1.1 million.

  • Sunshine Biopharma's Operating Income rose 178.42% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 3180.3%. This contributed to the annual value of -$5.8 million for FY2024, which is 2145.78% down from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Operating Income is -$1.1 million, which was up 178.42% from -$2.1 million recorded in Q2 2025.
  • Sunshine Biopharma's Operating Income's 5-year high stood at -$279631.0 during Q4 2021, with a 5-year trough of -$23.4 million in Q4 2022.
  • Over the past 5 years, Sunshine Biopharma's median Operating Income value was -$1.2 million (recorded in 2022), while the average stood at -$2.3 million.
  • As far as peak fluctuations go, Sunshine Biopharma's Operating Income plummeted by 825515.73% in 2022, and later surged by 9491.85% in 2023.
  • Sunshine Biopharma's Operating Income (Quarter) stood at -$279631.0 in 2021, then tumbled by 8255.16% to -$23.4 million in 2022, then skyrocketed by 94.92% to -$1.2 million in 2023, then tumbled by 71.64% to -$2.0 million in 2024, then skyrocketed by 46.68% to -$1.1 million in 2025.
  • Its Operating Income was -$1.1 million in Q3 2025, compared to -$2.1 million in Q2 2025 and -$1.3 million in Q1 2025.